ArticleAnatolian journal of cardiology2026
The Impact of Intravenous Agitated Saline Contrast Echocardiography on Subclinical Neuronal Injury Determined By Neuron-Specific Enolase.
Article in Anatolian journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatent foramen ovale (PFO) is a congenital defect of the interatrial septum with 25%-30% prevalence. Diagnostic echocardiography involves the injection of agitated saline, and microbubble passage from the right to the left atrium is monitored. The reliability of this method has been questioned in case series, with a low incidence (0.062%) of generally transient, mild clinical cerebrovascular events. This study aimed to examine whether transthoracic echocardiography, which was performed on patients with PFO and atrial septal aneurysm (ASA) without neurological history, and healthy controls can cause silent neuronal injury by evaluating neuronspecific enolase (NSE) with saline contrast echocardiography (SCE).
methodsFifty-two patients who underwent SCE for color flow through the interatrial septum or prominent interatrial septal aneurysm and were diagnosed with PFO were included. Fifty-one control patients without PFO or ASA were included. Serum samples were collected from the patients before and 12 hours after the SCE test, and NSE levels were measured by Enzyme Linked Immunosorbent Assay (ELISA).
resultsMedian baseline NSE levels were 6.4 (2.8-9.6) ng/mL in the PFO/ASA group and 5.3 (3.6-9.1) ng/mL in controls. At 12 hours, median NSE levels remained similar (6.6 (3.8-11.5) vs. 5.8 (4.6-9.6) ng/mL; P = .90). The median change in NSE (ΔNSE) did not differ between groups [1.19 (-1.01 to 2.23) vs. 0.73 (-1.16 to 2.25) ng/mL; P = .58]. There was no relationship between age, presence of interatrial septal aneurysm, mitral annulus calcification, number of bubbles passed in the SCE test, and baseline and 12-h change in NSE levels (P = .926). Neuronspecific enolase level changes were found to be correlated between groups (P < .001).
conclusionThis study is the first to evaluate whether SCE causes silent neuronal injury. It is suggested that when evaluated with NSE, the SCE method is safe and does not cause silent neuronal injury in patients without underlying neuronal susceptibility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.